MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharma company developing precision peptide therapies for endocrine and metabolic disorders, will present at the Jefferies 2026 Global Healthcare Conference in New York City.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharma company developing precision peptide therapies for endocrine and metabolic disorders, will present at the Jefferies 2026 Global Healthcare Conference in New York City.
The company’s leadership will present on June 3, 2026, with a live webcast and 90-day replay available.
Details
News Market Reaction – MBX
On May 26, the day this news came out, MBX closed 0.31% below the previous close.
Data tracked by StockTitan Argus for the May 26 session.
Key Figures
- Conference date
- June 3, 2026
- Jefferies 2026 Global Healthcare Conference presentation date
- Presentation start time
- 8:10 a.m. ET
- Start time of Jefferies conference presentation
- Presentation end time
- 8:40 a.m. ET
- End time of Jefferies conference presentation
- Webcast archive period
- approximately 90 days
- Duration replay remains available on company website
Historical Context
-
Initial Phase 1 MBX 4291 obesity data and portfolio expansion plans.
-
Q1 2026 results, $440M cash runway into 2029, canvuparatide progress.
-
Appointment of Chief Commercial Officer and related equity inducement grant.
-
Announcement of Obesity Day to discuss obesity portfolio and PEP platform.
-
FY 2025 results, $459.1M cash, ongoing clinical advancement across programs.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARMEL, Ind. and BURLINGTON, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at the Jefferies 2026 Global Healthcare Conference in New York City.
The presentation will take place on Wednesday, June 3, 2026, from 8:10 a.m. to 8:40 a.m. ET.
The live webcast can be accessed under the Events section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. A replay of the webcast will be accessible approximately two hours following the conclusion of the presentation and will remain archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism preparing for Phase 3 development; and an obesity portfolio that includes MBX 4291 in Phase 1 development and MBX 5765 in preclinical development, as well as additional discovery candidates. The Company is based in Carmel, Indiana and Burlington, Massachusetts. To learn more, please visit the company website at www.mbxbio.com and follow it on LinkedIn.
Media Contact:
George Shea
We. Communications
gshea@wecommunications.com
(937) 232-4889
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.